SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

Javier Escalada

doi:10.1007/s13300-022-01281-5

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

Diabetes Ther. 2022 Jul;13(Suppl 1):1-3. doi: 10.1007/s13300-022-01281-5. Epub 2022 Jun 15.

Author

Javier Escalada^{1

2}

Affiliations

¹ Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain. fescalada@unav.es.
² CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. fescalada@unav.es.

No abstract available

Keywords: Cardiorenal; Cardiorenal continuum; Cardiovascular disease; Chronic kidney disease; Heart failure; Kidney disease; Morbidity; Mortality; SGLT2 inhibitors; Type 2 diabetes.

Publication types

Editorial